Human Four And A Half LIM Domains Protein 1 (FHL1) ELISA Kit | FHL1 elisa kit

Human Four And A Half LIM Domains Protein 1 (FHL1) ELISA Kit

Cat. Num. AAA2020002

• Gene Names: Fhl1; SLIM1
• Reactivity: Human
• Synonyms: Four And A Half LIM Domains Protein 1 (FHL1); Human Four And A Half LIM Domains Protein 1 (FHL1) ELISA Kit; FHL1B; KYO-T; SLIM1; XMPMA; FLH1A; LIM Protein SLIMMER; Skeletal muscle LIM-protein 1; FHL1 elisa kit

• Reactivity: Human
• Specificity: This assay has high sensitivity and excellent specificity for detection of FHL1. No significant cross-reactivity or interference between FHL1 and analogues was observed.
• Sequence Length: 296

• Samples: Human tissue homogenates, cell lysates and other biological fluids
• Assay Type: Quantitative Sandwich
• Detection Range: 0.156-10ng/mL
• Sensitivity: < 0.058ng/mL
• Intra-assay Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level FHL1 were tested 20 times on one plate, respectively. Intra-Assay: CV<10%
• Inter-assay Precision: Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level FHL1 were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100. Inter-Assay: CV<12%
• Preparation and Storage: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. ; To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Typical Testing Data/Standard Curve (for reference only)

Related Product Information for FHL1 elisa kit

Intended Uses: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of FHL1 in human tissue homogenates, cell lysates and other biological fluids.

Principle of the Assay: The microplate provided in this kit has been pre-coated with an antibody specific to FHL1. Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to FHL1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain FHL1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +/- 10nm. The concentration of FHL1 in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Product Categories/Family for FHL1 elisa kit

Signal Transduction

NCBI and Uniprot Product Information

• NCBI GI #: 76781465
• NCBI GeneID: 25177
• NCBI Accession #: NP_001029098.1
• NCBI GenBank Nucleotide #: NM_001033926.2
• Molecular Weight: 31,904 Da
• NCBI Official Full Name: four and a half LIM domains protein 1 isoform 1
• NCBI Official Synonym Full Names: four and a half LIM domains 1
• NCBI Official Symbol: Fhl1
• NCBI Official Synonym Symbols: SLIM1
• NCBI Protein Information: four and a half LIM domains protein 1
• UniProt Protein Name: Four and a half LIM domains protein 1
• Protein Family: Fork head transcription factor
• UniProt Gene Name: Fhl1
• UniProt Synonym Gene Names: FHL-1
• UniProt Entry Name: FHL1_RAT

NCBI Description

contains a zinc binding domain; expressed in skeletal muscle [RGD, Feb 2006]

Uniprot Description

FHL1: May have an involvement in muscle development or hypertrophy. Defects in FHL1 are the cause of X-linked dominant scapuloperoneal myopathy (SPM). Scapuloperoneal syndrome (SPS) was initially described more than 120 years ago by Jules Broussard as 'une forme hereditaire d'atrophie musculaire progressive' beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. The etiology of this condition remains unclear. Defects in FHL1 are the cause of X-linked myopathy with postural muscle atrophy (XMPMA). Myopathies are inherited muscle disorders characterized by weakness and atrophy of voluntary skeletal muscle, and several types of myopathy also show involvement of cardiac muscle. XMPMA is a distinct form of adult-onset X-linked recessive myopathy with several features in common with other myopathies, but the presentation of a pseudoathletic phenotype, scapuloperoneal weakness, and bent spine is unique and might render the clinical phenotype distinguishable from other myopathies. Defects in FHL1 are the cause of X-linked severe early- onset reducing body myopathy (RBM). RBM is a rare muscle disorder causing progressive muscular weakness and characteristic intracytoplasmic inclusions in myofibers. Clinical presentations of RBM have ranged from early onset fatal to childhood onset to adult onset cases. Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (CO-RBM). This disorder is allelic to severe early-onset reducing body myopathy (RBM). 5 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell development/differentiation

Cellular Component: focal adhesion; cytoplasm; plasma membrane; nucleus

Molecular Function: zinc ion binding

Biological Process: multicellular organismal development; positive regulation of potassium ion transport; negative regulation of cell growth; cell differentiation